查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1964075

氢可酮药物市场－全球产业规模、份额、趋势、机会、预测：按产品、应用、地区和竞争对手划分，2021-2031年

Morphine Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球氢可酮药品市场预计将从 2025 年的 267.8 亿美元成长到 2031 年的 358.1 亿美元，复合年增长率为 4.96%。

氢可酮是一种从罂粟提取的强效鸦片类镇痛药，是治疗方法严重急性和慢性疼痛的基础药物，尤其是在安宁疗护和癌症治疗领域。慢性疾病在全球日益加重，老龄化社会对永续疼痛管理策略的需求不断增长，以及安宁疗护服务在国际医疗体系中的重要性日益凸显，这些因素共同推动了吗啡市场的成长，巩固了其作为标准治疗药物的地位。

市场概览
预测期 2027-2031
市场规模：2025年 267.8亿美元
市场规模：2031年 358.1亿美元
复合年增长率：2026-2031年 4.96%
成长最快的细分市场 缓解疼痛
最大的市场 北美洲

另一方面，全球对阿片类药物成瘾和滥用问题的担忧，导致严格的法规结构和供应链失衡，这给市场扩张带来了重大障碍。这些监管壁垒造成许多地区的生产能力与患者供应之间存在缺口，限制了患者获得药物的机会。根据国际麻醉药品管制局的数据，到2025年，全球生产的氢可酮中只有18%将直接用于镇痛，凸显了用于基本医疗的吗啡生产能力严重不足。

市场驱动因素

慢性疼痛和癌症发生率的上升是全球氢可酮药物市场的主要驱动力，导致对鸦片类镇痛药的需求迫切增加。随着恶性肿瘤发生率的上升，尤其是在筛检率高的已开发国家，对积极疼痛管理通讯协定和药用级氢可酮的需求持续成长。例如，美国癌症协会于2025年1月发布的《2025年癌症事实与数据》报告预测，光是在美国，每年新增癌症病例就将超过200万例。为了满足不断增长的临床需求，主要生产商正在提高产量。 Hikma Pharmaceuticals在其2025年2月发布的中期财务报告中指出，其2024年註射剂销售额增长9%，达到13.06亿美元，反映出重症监护领域的强劲增长势头。

同时，对安宁疗护和临终关怀服务的需求不断增长，推动了市场发展，其关注点正转向以舒适为导向的干预措施，而氢可酮仍然是临终疼痛管理的黄金标准。儘管临终关怀机构已融入医疗保健基础设施，但安宁疗护的需求与其可近性之间仍存在显着差距。根据国际麻醉药品管制局 (INCB) 年度报告的分析（该报告由国际药物政策联盟 (IDPC) 于 2025 年 6 月发布），全球仅有 33,547 公斤氢可酮用于安宁疗护，远低于估计的最低合理消费量 43,000 公斤。这种差距为能够克服监管复杂性以满足这一未被满足的需求的供应商带来了巨大的商机。

市场挑战

为防止阿片类药物滥用而建立的严格法规结构，是氢可酮市场扩张的主要障碍。这些法规带来了复杂的合规负担，并使供应链更加复杂，导致氢可酮的分销对生产商而言既困难又成本高昂。儘管其目的是为了预防成瘾，但却造成了僵化的贸易环境，使得必要的镇痛药分销经常出现延误或中断。因此，生产者无法有效地服务临床需求高的地区，导致收入成长停滞，并在安宁疗护需求日益增长的地区阻碍了市场渗透。

这些限制性政策造成了全球医疗保健需求与实际产品供应之间的严重失衡。优先控製而非可及性意味着，即使生产能力充足，产品也常常无法送达患者手中。国际麻醉品管制局（INCB）近期发布的经销资料印证了这项物流瓶颈。该局报告称，到2024年，全球约78%的人口居住在经销法律限制阿片类止痛药取得的国家。这项数据凸显了监管障碍如何透过人为抑制消费直接阻碍市场规模的扩大。

市场趋势

全球氢可酮市场正因新型植入式和鞘内给药系统的出现而重组。这些系统为顽固性疼痛提供了标靶治疗方案。临床医师越来越避免全身给药，转而直接鞘内注射氢可酮，从而在最大限度减少副作用的同时，优化恶性疼痛的疗效。可程式设计泵浦技术在长期给药方面的应用也推动了这项转变。根据Medtronic2025年6月发布的《2024年标靶药物输送系统产品性能报告》，该公司註册登记系统追踪了10,793名使用这些系统的患者，其中17.0%的植入专门用于治疗恶性疼痛。这表明，对于复杂的癌症疾病，人们越来越依赖先进的给药机制。

同时，居家临终关怀中氢可酮使用量的增加显着稳定了其供应。随着医疗保健系统将临终关怀分散化，氢可酮仍然是临终关怀中必不可少的治疗药物，监管机构正被敦促保护其供应。与其他因滥用担忧而面临减产的鸦片类药物不同，氢可酮的配额得以维持，以确保居家病患的持续供应。美国缉毒局（DEA）于2024年12月发布的「2025财年总生产配额」维持了氢可酮的生产配额不变，以满足合法的医疗需求。同时，其他鸦片类药物（例如羟考酮）的配额有所减少，这凸显了氢可酮在不断发展的居家医疗领域中的关键作用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球氢可酮药物市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 产品特定型鸦片类药物（即时释/短效鸦片类药物、缓释/长效型鸦片类药物）
    • 应用范围（缓解疼痛、麻醉、止咳、止泻、成瘾治疗）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美氢可酮药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲氢可酮药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区氢可酮药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲氢可酮药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲氢可酮药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球氢可酮药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi SA
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Endo, Inc.
  • Verve Health Care Ltd.
  • Mallinckrodt Pharmaceuticals

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23843

The Global Morphine Drugs Market is projected to expand from USD 26.78 Billion in 2025 to USD 35.81 Billion by 2031, reflecting a CAGR of 4.96%. Morphine, a potent opioid analgesic derived from the opium poppy, serves as a fundamental treatment for severe acute and chronic pain, particularly within palliative and cancer care environments. This market growth is underpinned by the increasing global burden of chronic diseases and an aging population that necessitates consistent pain management strategies, alongside a growing emphasis on palliative care services within international healthcare systems that solidifies the drug's status as a standard of care.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 26.78 Billion
Market Size 2031USD 35.81 Billion
CAGR 2026-20314.96%
Fastest Growing SegmentPain Relief
Largest MarketNorth America

Conversely, market expansion faces significant hurdles due to strict regulatory frameworks and supply chain disparities stemming from global concerns regarding opioid addiction and misuse. These regulatory barriers often limit accessibility, creating a disconnect between manufacturing capabilities and patient availability across many regions. Data from the International Narcotics Control Board indicates that in 2025, only 18 percent of globally manufactured morphine was utilized directly for pain relief, highlighting a severe underutilization of production capacity intended for essential medical treatment.

Market Driver

The escalating prevalence of chronic pain and cancer serves as a primary catalyst for the Global Morphine Drugs Market, creating an urgent need for increased opioid analgesic production. As the incidence of malignant neoplasms rises, particularly in developed nations with high detection rates, the demand for aggressive pain management protocols and pharmaceutical-grade morphine continues to intensify. For instance, the American Cancer Society's 'Cancer Facts & Figures 2025' report from January 2025 projects over 2 million new cancer diagnoses in the United States alone for the year. To meet these growing clinical requirements, major manufacturers are scaling up operations; Hikma Pharmaceuticals reported in their February 2025 preliminary results that their Injectables business revenue grew by 9 percent to $1.306 billion in 2024, reflecting robust activity in the critical care sector.

Simultaneously, the rising demand for palliative and end-of-life care services propels market momentum, shifting focus toward comfort-oriented interventions where morphine remains the gold standard for terminal pain. Despite the integration of hospice units into healthcare infrastructures, a distinct gap persists between palliative necessity and accessibility. According to a June 2025 analysis by the International Drug Policy Consortium referencing the annual INCB report, only 33,547 kilograms of morphine are utilized globally for palliative care, falling short of the estimated 43,000 kilograms required for minimally adequate consumption. This disparity highlights a substantial opportunity for suppliers capable of navigating regulatory complexities to meet this unmet demand.

Market Challenge

Stringent regulatory frameworks established to mitigate opioid misuse act as a primary obstruction to the expansion of the morphine market. These regulations impose complex compliance burdens that complicate the supply chain, making the distribution of morphine administratively difficult and costly for manufacturers. Although the intent is to prevent addiction, the practical result is a rigid trade environment where the movement of essential analgesics is frequently delayed or halted. Consequently, manufacturers are prevented from effectively serving regions with high clinical demand, thereby capping revenue growth and stifling market penetration in areas where palliative care needs are rising.

The impact of these restrictive policies leads to a severe imbalance between global medical needs and actual product availability. The prioritization of control over accessibility means that despite adequate manufacturing capabilities, the product often fails to reach the patient base. This logistical bottleneck is substantiated by recent distribution data from the International Narcotics Control Board, which reported in 2024 that approximately 78 percent of the global population lived in countries with inadequate access to opioid analgesics due to restrictive distribution laws. This statistic underscores how regulatory barriers directly hamper market volume by artificially suppressing consumption rates.

Market Trends

The Global Morphine Drugs Market is being reshaped by the emergence of novel implantable and intrathecal delivery systems, which provide targeted alternatives for refractory pain. Clinicians are increasingly bypassing systemic administration to deliver morphine directly to the intrathecal space, optimizing efficacy for malignant pain while minimizing adverse effects, a shift supported by the adoption of programmable pump technologies for long-term dosing. According to Medtronic's June 2025 'Targeted Drug Delivery Systems 2024 Product Performance Report', the company's registry tracked 10,793 patients utilizing these systems, with 17.0 percent of implants specifically indicated for the treatment of malignant pain, underscoring the growing reliance on sophisticated delivery mechanisms for complex cancer conditions.

Concurrently, the increasing utilization of morphine in home-based palliative care settings is driving a distinct stabilization in supply. As healthcare systems decentralize end-of-life treatment, morphine remains the essential therapeutic agent for hospice care, prompting regulatory bodies to protect its availability. Unlike other opioids facing production cuts due to misuse concerns, morphine quotas are being maintained to ensure continuity for patients in home-based settings. The Drug Enforcement Administration's '2025 Aggregate Production Quotas', released in December 2024, kept the production quota for morphine unchanged to meet legitimate medical needs, whereas quotas for other opioids like oxycodone were reduced, highlighting the critical role of morphine in the expanding home-care sector.

Key Market Players

  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi S.A
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Endo, Inc.
  • Verve Health Care Ltd.
  • Mallinckrodt Pharmaceuticals

Report Scope

In this report, the Global Morphine Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Morphine Drugs Market, By Product

  • Immediate Release/ Short Acting Opioids
  • Extended Release/Long-Acting Opioids

Morphine Drugs Market, By Application

  • Pain Relief
  • Anesthesia
  • Cough Suppression
  • Diarrhoea Suppression
  • De-addiction

Morphine Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Morphine Drugs Market.

Available Customizations:

Global Morphine Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Morphine Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Immediate Release/ Short Acting Opioids, Extended Release/Long-Acting Opioids)
    • 5.2.2. By Application (Pain Relief, Anesthesia, Cough Suppression, Diarrhoea Suppression, De-addiction)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Morphine Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Morphine Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Morphine Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Morphine Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Morphine Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Morphine Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Morphine Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Morphine Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Morphine Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Morphine Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Morphine Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Morphine Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Morphine Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Morphine Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Morphine Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Morphine Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Morphine Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Morphine Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Morphine Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Morphine Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Morphine Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Morphine Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Morphine Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Morphine Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Morphine Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Hikma Pharmaceuticals plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. AbbVie Inc.
  • 15.4. Sanofi S.A
  • 15.5. Viatris Inc.
  • 15.6. Sun Pharmaceutical Industries Ltd.
  • 15.7. Teva Pharmaceutical Industries Ltd.
  • 15.8. Endo, Inc.
  • 15.9. Verve Health Care Ltd.
  • 15.10. Mallinckrodt Pharmaceuticals

16. Strategic Recommendations

17. About Us & Disclaimer